Migraine and infertility, merging concepts in women's reproductive health: A narrative review.
in vitro fertilization
infertility
migraine
Journal
Headache
ISSN: 1526-4610
Titre abrégé: Headache
Pays: United States
ID NLM: 2985091R
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
11
07
2022
accepted:
22
08
2022
pubmed:
7
10
2022
medline:
15
12
2022
entrez:
6
10
2022
Statut:
ppublish
Résumé
The objective is to examine issues around treating infertility in patients with migraine. Women outnumber men in migraine diagnosis with a 3:1 ratio; the disease is commonly expressed in women of child-bearing age and is influenced by changes in circulating hormones. Infertility is also common, and the use of treatment options, such as assisted reproductive technology, have expanded exponentially in recent years. We summarized the literature around the effect of infertility treatments on headache in the general population and migraine population. We also discuss sociobehavioral, economic, and biological factors affecting fertility in patients with migraine, describe infertility protocols, and propose areas of focus for future research. We searched PubMed for the combined key terms in vitro fertilization or assisted reproductive technology AND migraine, or headache. The search included all dates and specified English-language results only. Migraine may negatively influence family planning and fertility. Patients face obstacles stemming from the impact of migraine on social relationships and the interference of preventive medications on pregnancy. Migraine may also be associated with an increased prevalence of endocrine disorders which in turn affect fertility. Moreover, infertility treatments are associated with mild headache as a side effect. In addition, we found only one retrospective study demonstrating an increase in headache frequency during in vitro fertilization in the migraine population. We determined that there is little research focused specifically on migraine headache exacerbation and other migraine-associated health outcomes with infertility treatment. This topic merits further interdisciplinary exploration.
Sections du résumé
OBJECTIVE
The objective is to examine issues around treating infertility in patients with migraine.
BACKGROUND
Women outnumber men in migraine diagnosis with a 3:1 ratio; the disease is commonly expressed in women of child-bearing age and is influenced by changes in circulating hormones. Infertility is also common, and the use of treatment options, such as assisted reproductive technology, have expanded exponentially in recent years.
METHODS
We summarized the literature around the effect of infertility treatments on headache in the general population and migraine population. We also discuss sociobehavioral, economic, and biological factors affecting fertility in patients with migraine, describe infertility protocols, and propose areas of focus for future research. We searched PubMed for the combined key terms in vitro fertilization or assisted reproductive technology AND migraine, or headache. The search included all dates and specified English-language results only.
RESULTS
Migraine may negatively influence family planning and fertility. Patients face obstacles stemming from the impact of migraine on social relationships and the interference of preventive medications on pregnancy. Migraine may also be associated with an increased prevalence of endocrine disorders which in turn affect fertility. Moreover, infertility treatments are associated with mild headache as a side effect. In addition, we found only one retrospective study demonstrating an increase in headache frequency during in vitro fertilization in the migraine population.
CONCLUSIONS
We determined that there is little research focused specifically on migraine headache exacerbation and other migraine-associated health outcomes with infertility treatment. This topic merits further interdisciplinary exploration.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1247-1255Informations de copyright
© 2022 American Headache Society.
Références
Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496-505.
Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631-649.
Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349.
Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Hum Reprod Update. 2015;21(4):411-426.
Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):e1001356.
Jones HW Jr, Cooke I, Kempers R, Brinsden P, Saunders D. International Federation of Fertility Societies Surveillance 2010: preface. Fertil Steril. 2011;95(2):491.
Thurston L, Abbara A, Dhillo WS. Investigation and management of subfertility. J Clin Pathol. 2019;72(9):579-587.
Sunderam S, Kissin DM, Crawford SB, et al. Assisted reproductive technology surveillance - United States, 2015. MMWR Surveill Summ. 2018;67(3):1-28.
Ishii R, Schwedt TJ, Kim SK, Dumkrieger G, Chong CD, Dodick DW. Effect of migraine on pregnancy planning: insights from the American registry for migraine research. Mayo Clin Proc. 2020;95(10):2079-2089.
Smith R. Impact of migraine on the family. Headache. 1998;38(6):423-426.
Buse DC, Scher AI, Dodick DW, et al. Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. Mayo Clin Proc. 2016;91:596-611.
Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia. 2003;23(6):429-440.
Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58(5):700-714.
Stang PE, Crown WH, Bizier R, Chatterton ML, White R. The family impact and costs of migraine. Am J Manag Care. 2004;10(5):313-320.
Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health. 2009;12(1):55-64.
Crawford S, Boulet SL, Mneimneh AS, et al. Costs of achieving live birth from assisted reproductive technology: a comparison of sequential single and double embryo transfer approaches. Fertil Steril. 2016;105(2):444-450.
Wu AK, Odisho AY, Washington SL 3rd, Katz PP, Smith JF. Out-of-pocket fertility patient expense: data from a multicenter prospective infertility cohort. J Urol. 2014;191(2):427-432.
Wu AK, Elliott P, Katz PP, Smith JF. Time costs of fertility care: the hidden hardship of building a family. Fertil Steril. 2013;99(7):2025-2030.
Farley Ordovensky Staniec J, Webb NJ. Utilization of infertility services: how much does money matter? Health Serv Res. 2007;42(3 Pt 1):971-989.
Burch R. Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review. Headache. 2020;60(1):200-216.
de Vries LS, Rubio-Beltran E, MaassenVanDenBrink A. Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: implications for the efficacy and safety of novel antimigraine medications. Maturitas. 2021;145:73-77.
Yallampalli C, Chauhan M, Sathishkumar K. Calcitonin gene-related family peptides in vascular adaptations, uteroplacental circulation, and fetal growth. Curr Vasc Pharmacol. 2013;11(5):641-654.
Dong YL, Green KE, Vegiragu S, et al. Evidence for decreased calcitonin gene-related peptide (CGRP) receptors and compromised responsiveness to CGRP of fetoplacental vessels in preeclamptic pregnancies. J Clin Endocrinol Metab. 2005;90(4):2336-2343.
Glintborg D, Hass Rubin K, Nybo M, Abrahamsen B, Andersen M. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol. 2015;172(5):627-638.
Pourabolghasem S, Najmi S, Arami MA. Polycystic ovary syndrome and migraine headache, is there any correlation? Eur Neurol. 2009;61(1):42-45.
Ferrero S, Pretta S, Bertoldi S, et al. Increased frequency of migraine among women with endometriosis. Hum Reprod. 2004;19(12):2927-2932.
Tietjen GE, Bushnell CD, Herial NA, Utley C, White L, Hafeez F. Endometriosis is associated with prevalence of comorbid conditions in migraine. Headache. 2007;47(7):1069-1078.
Jenabi E, Khazaei S. Endometriosis and migraine headache risk: a meta-analysis. Women Health. 2020;60(8):939-945.
Hart R. PCOS and infertility. Panminerva Med. 2008;50(4):305-314.
Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am. 2012;39(4):535-549.
Cunningham J. Infertility: a primer for primary care providers. JAAPA. 2017;30(9):19-25.
Ozturk S. Selection of competent oocytes by morphological criteria for assisted reproductive technologies. Mol Reprod Dev. 2020;87(10):1021-1036.
Wilcox J, Potter D, Moore M, Ferrande L, Kelly E, Group CII. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril. 2005;84(1):108-117.
Amir BY, Yaacov B, Guy B, Gad P, Itzhak W, Gal I. Headaches in women undergoing in vitro fertilization and embryo-transfer treatment. Headache. 2005;45(3):215-219.
Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab. 1983;57(4):792-796.
Droesch K, Muasher SJ, Brzyski RG, et al. Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization. Fertil Steril. 1989;51(2):292-297.
Levens ED, Whitcomb BW, Kort JD, Materia-Hoover D, Larsen FW. Microdose follicular flare: a viable alternative for normal-responding patients undergoing in vitro fertilization? Fertil Steril. 2009;91(1):110-114.
Elassar A, Mann JS, Engmann L, Nulsen J, Benadiva C. Luteal phase estradiol versus luteal phase estradiol and antagonist protocol for controlled ovarian stimulation before in vitro fertilization in poor responders. Fertil Steril. 2011;95(1):324-326.
Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod. 1997;12(11):2359-2365.
Youssef MA, van Wely M, Mochtar M, et al. Low dosing of gonadotropins in in vitro fertilization cycles for women with poor ovarian reserve: systematic review and meta-analysis. Fertil Steril. 2018;109(2):289-301.
Chang EM, Han JE, Won HJ, Kim YS, Yoon TK, Lee WS. Effect of estrogen priming through luteal phase and stimulation phase in poor responders in in-vitro fertilization. J Assist Reprod Genet. 2012;29(3):225-230.
Weitzman VN, Engmann L, DiLuigi A, Maier D, Nulsen J, Benadiva C. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes. Fertil Steril. 2009;92(1):226-230.
Dragisic KG, Davis OK, Fasouliotis SJ, Rosenwaks Z. Use of a luteal estradiol patch and a gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation for in vitro fertilization in poor responders. Fertil Steril. 2005;84(4):1023-1026.
Shastri SM, Barbieri E, Kligman I, Schoyer KD, Davis OK, Rosenwaks Z. Stimulation of the young poor responder: comparison of the luteal estradiol/gonadotropin-releasing hormone antagonist priming protocol versus oral contraceptive microdose leuprolide. Fertil Steril. 2011;95(2):592-595.
Branigan EF, Estes MA. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression. Fertil Steril. 2000;73(3):587-590.
Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.
Sacco S, Ornello R, Ripa P, et al. Migraine and risk of ischaemic heart disease: a systematic review and meta-analysis of observational studies. Eur J Neurol. 2015;22(6):1001-1011.
Lankreijer K, D'Hooghe TM, Apers S, Sermeus W, Repping S, Dancet EA. Hormonal medication in medically assisted reproduction: a systematic review of assessments from patients. Reprod Biomed Online. 2019;38(3):341-363.
Gillies PS, Faulds D, Balfour JA, Perry CM. Ganirelix. Drugs 2000;59(1):107-111; discussion 112-103.
A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod. 1998;13(11):3023-3031.
Oberye JJ, Mannaerts BM, Huisman JA, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril. 1999;72(6):1006-1012.
Tapanainen J, Hovatta O, Juntunen K, et al. Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study. Hum Reprod. 1993;8(12):2052-2055.
von Wolff M, Nitzschke M, Stute P, Bitterlich N, Rohner S. Low-dosage clomiphene reduces premature ovulation rates and increases transfer rates in natural-cycle IVF. Reprod Biomed Online. 2014;29(2):209-215.
Siedentopf F, Horstkamp B, Stief G, Kentenich H. Clomiphene citrate as a possible cause of a psychotic reaction during infertility treatment. Hum Reprod. 1997;12(4):706-707.
Jones T, Ho JR, Gualtieri M, et al. Clomiphene stair-step protocol for women with polycystic ovary syndrome. Obstet Gynecol. 2018;131(1):91-95.
Aboelroose AA, Ibrahim ZM, Madny EH, Elmazzahy AM, Taha OT. A randomized clinical trial of sildenafil plus clomiphene citrate to improve the success rate of ovulation induction in patients with unexplained infertility. Int J Gynaecol Obstet. 2020;150(1):72-76.
Nahid L, Sirous K. Comparison of the effects of letrozole and clomiphene citrate for ovulation induction in infertile women with polycystic ovary syndrome. Minerva Ginecol. 2012;64(3):253-258.
Satirapod C, Wingprawat S, Jultanmas R, Rattanasiri S, Jirawatnotai S, Choktanasiri W. Effect of estradiol valerate on endometrium thickness during clomiphene citrate-stimulated ovulation. J Obstet Gynaecol Res. 2014;40(1):96-101.
Gaul C, Stiller R, Erni S, Ettlin DA, Sandor PS. Cluster headache triggered by high-dose gestagens in the context of in vitro fertilization: a case report. Cephalalgia. 2007;27(12):1418-1420.
Check JH. Very unusual symptoms consistent with a possible migraine immediately following the injection of recombinant follitropin beta. Clin Exp Obstet Gynecol. 2016;43(4):484-485.
Haskell CM, Herrmann C Jr, Marsh GG. Clomiphene-induced neurological dysfunction. Lancet. 1977;2(8050):1227.
Purvin VA. Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol. 1995;113(4):482-484.
Roch LM 2nd, Gordon DL, Barr AB, Paulsen CA. Visual changes associated with clomiphene citrate therapy. Arch Ophthalmol. 1967;77(1):14-17.
Epstein MT, Hockaday JM, Hockaday TD. Migraine and reporoductive hormones throughout the menstrual cycle. Lancet. 1975;1(7906):543-548.
Silberstein SD. Sex hormones and headache. Rev Neurol. 2000;156(Suppl 4):4S30-4S41.
Pavlovic JM, Allshouse AA, Santoro NF, et al. Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. Neurology. 2016;87(1):49-56.
Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol. 2014;123(5):997-1002.
Bortoletto P, Prabhu M, Garry EM, Huybrechts KF, Anchan RM, Bateman BT. Opioid dispensing patterns after oocyte retrieval. Fertil Steril. 2018;110(5):905-909.
Lauritzen M. Spreading depression and migraine. Pathol Biol. 1992;40(4):332-337.
Hadjikhani N, Vincent M. Neuroimaging clues of migraine aura. J Headache Pain. 2019;20(1):32.
Harriott AM, Chung DY, Uner A, et al. Optogenetic spreading depression elicits trigeminal pain and anxiety behavior. Ann Neurol. 2021;89(1):99-110.
Krause DN, Warfvinge K, Haanes KA, Edvinsson L. Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP. Nat Rev Neurol. 2021;17(10):621-633.
Sandweiss AJ, Cottier KE, McIntosh MI, et al. 17-beta-estradiol induces spreading depression and pain behavior in alert female rats. Oncotarget. 2017;8(69):114109-114122.
Hu X, Zhou Y, Zhao H, Peng C. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci. 2017;38(1):33-40.
Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review. Headache. 2018;58(1):5-21.
Bousser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The international headache society task force on combined Oral Contraceptives & Hormone Replacement Therapy. Cephalalgia. 2000;20(3):155-156.
Kumar P, Sait SF, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci. 2011;4(2):70-75.
Rollene NL, Khan Z, Schroeder DR, Cutrer FM, Coddington CC. Migraines and ovarian hyperstimulation syndrome: a dopamine connection. Fertil Steril. 2011;95(1):417-419.
Bandoli G, Baer RJ, Gano D, Pawlowski LJ, Chambers C. Migraines during pregnancy and the risk of maternal stroke. JAMA Neurol. 2020;77(9):1177-1179.
Wabnitz A, Bushnell C. Migraine, cardiovascular disease, and stroke during pregnancy: systematic review of the literature. Cephalalgia. 2015;35(2):132-139.
Williams MA, Peterlin BL, Gelaye B, Enquobahrie DA, Miller RS, Aurora SK. Trimester-specific blood pressure levels and hypertensive disorders among pregnant migraineurs. Headache. 2011;51(10):1468-1482.
Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ. 2009;338:b664.
Gui J, Ling Z, Hou X, Fan Y, Xie K, Shen R. In vitro fertilization is associated with the onset and progression of preeclampsia. Placenta. 2020;89:50-57.
Chen XK, Wen SW, Bottomley J, Smith GN, Leader A, Walker MC. In vitro fertilization is associated with an increased risk for preeclampsia. Hypertens Pregnancy. 2009;28(1):1-12.
Johnson KM, Hacker MR, Thornton K, Young BC, Modest AM. Association between in vitro fertilization and ischemic placental disease by gestational age. Fertil Steril. 2020;114(3):579-586.
Headache classification Committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.